Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00866333 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma
A Phase 2 study, sponsored by Syndax Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
NCT00866333 is a Phase 2 study that was terminated before completion, run by Syndax Pharmaceuticals. The registered enrollment target is 49 participants.
The verdict
NCT00866333, a Phase 2 study, was terminated before completion, sponsored by Syndax Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of entinostat, SNDX-275, in patients with relapsed or refractory Hodgkin's lymphoma.
Interventions
- DRUG Entinostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2009-04-13 |
| Est. Completion | 2013-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00866333
The ClinicalTrials.gov registry entry for NCT00866333 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Entinostat is the first listed.
NCT00866333 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00866333 about?
NCT00866333 is a clinical study titled "A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphoma". This study will evaluate the efficacy and safety of entinostat, SNDX-275, in patients with relapsed or refractory Hodgkin's lymphoma.
What is the current status of trial NCT00866333?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2009-04-13. Estimated completion is 2013-02-08.
What interventions are being tested in trial NCT00866333?
The interventions under investigation include: Entinostat (DRUG).
Who is sponsoring clinical trial NCT00866333?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.